European Commission Approves TEPMETKO^® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

Merck KGaA, announced that the European Commission has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients with advanced NSCLC harboring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping.